search
Back to results

Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome

Primary Purpose

Neonatal Respiratory Distress

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Misoprostol
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Neonatal Respiratory Distress focused on measuring Misoprostol, neonatal, respiratory distress, cesarean section

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

All pregnant women who are planned for elective (planned& pre labor) cesarean section at 34 -37 weeks gestation.

Exclusion Criteria:

  1. Pregnancies with known fetal malformation/s or chromosomal aberrations.
  2. Presence of absolute contraindication for use of misoprostol.(i.e known hypersensitivity to the drug)
  3. Women before 34 and after 37 weeks gestation .
  4. Non reassuring cardiotocogram immediately before recruitment.
  5. multiple pregnancies.

Sites / Locations

  • women health center,Assiut universityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

study group

control group

Arm Description

For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS

For the control group mothers enrolled will receive nothing.

Outcomes

Primary Outcome Measures

1- Rate of Neonatal Intensive Care Unit admission for neonatal respiratory distress.
The number of neonates who need Neonatal Intensive Care Unit admission in each study group

Secondary Outcome Measures

Full Information

First Posted
July 30, 2017
Last Updated
January 4, 2018
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT03239327
Brief Title
Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome
Official Title
Vaginal Misoprostol Before Elective Cesarean Section to Improve Neonatal Respiratory Outcomes . Randomized Controlled Clinical Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Unknown status
Study Start Date
June 2016 (Actual)
Primary Completion Date
January 2018 (Anticipated)
Study Completion Date
January 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Project summary: Objective: To test the hypothesis that administration of vaginal Misoprostol before elective cesarean section will improve the neonatal respiratory outcomes in late preterm and early term neonates through induction of catecholamine surge. Design: Randomized controlled clinical trial. Setting: Women health center ,Assiut university hospital. Patients: mothers planned for cesarean section at 34 - 37weeks. Intervention: two hundred and ninety two women will be randomly allocated to receive either 50 micrograms of Misoprostol per vagina within one hour before cesarean section (study group; n= 146) or receive nothing (control group; n = 146) . Main outcome measure: Apgar score at 1 and 5 minutes.
Detailed Description
Methodology: After a written informed consent obtained, women who are fitting the inclusion criteria will be randomly allocated using sealed, coded, opaque and sequentially numbered envelopes containing computer generated random numbers into either the study group or the control group. For the study group the enrolled women will receive 50 microgram misoprostol vaginally within 60 minutes before CS. For the control group mothers enrolled will receive nothing. Observation and data collection: Cardiotocographic monitoring will be undertaken after maternal misoprostol administration to detect any evidence of uterine hyperstimulation and fetal distress. Ritodrine IV will be used as a tocolytic agent in case of uterine tachysystole. 100 mg of ritodrine will be added to 500 ml of 0.5% dextrose, the solution will be administered as following: 5 drops / minute in the 1st 10 minutes. 10 drops / minute in the next 10 minutes then 15 drops / minute . The clinician should adjust the infusion rate so that the pulse rate doesn't exceed 120b/min and lung bases are free of crepitations. The surgical and anesthetic teams will be in a state of complete readiness for the ECS from the time of maternal misoprostol administration after enrollment. Details on maternal fluid-electrolyte status during ECS will be recorded as maternal fluid overload is reported to be associated with respiratory distress in the newborn. (SinghiS,Chookang E;1984) blood loss during and 1 hour after the operation will be estimated. Maternal data: Patient name, hospital number, age, parity, gestational age, any medical disorder and indication of CS. Neonatal observations: delivery room care details will be noted, neonatal heart rate, respiratory rate, and signs of respiratory distress- for example, grunting, chest wall retractions, nasal flaring- will be recorded hourly in the postnatal ward for eight hours and once only at 24 hours of age after delivery. Management of a neonate with respiratory distress (defined as respiratory rate at rest.60/min and/or signs of respiratory distress) will be left to the neonatal team. Severity of illness, provisional and final diagnosis, and outcome (death/discharge home/transfer to other hospital) will be recorded if any neonate would be admitted to the neonatal intensive care unit for respiratory distress.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neonatal Respiratory Distress
Keywords
Misoprostol, neonatal, respiratory distress, cesarean section

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
292 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
study group
Arm Type
Experimental
Arm Description
For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
Arm Title
control group
Arm Type
No Intervention
Arm Description
For the control group mothers enrolled will receive nothing.
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Other Intervention Name(s)
Prostaglandin E1,Cytotec
Primary Outcome Measure Information:
Title
1- Rate of Neonatal Intensive Care Unit admission for neonatal respiratory distress.
Description
The number of neonates who need Neonatal Intensive Care Unit admission in each study group
Time Frame
During the first 24 hours of life.

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All pregnant women who are planned for elective (planned& pre labor) cesarean section at 34 -37 weeks gestation. Exclusion Criteria: Pregnancies with known fetal malformation/s or chromosomal aberrations. Presence of absolute contraindication for use of misoprostol.(i.e known hypersensitivity to the drug) Women before 34 and after 37 weeks gestation . Non reassuring cardiotocogram immediately before recruitment. multiple pregnancies.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed Makhlouf, professor
Phone
0882414616
Email
amakhloufsalama@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed Makhlouf, professor
Organizational Affiliation
women health center,Assiut university,Assiut,Egypt
Official's Role
Principal Investigator
Facility Information:
Facility Name
women health center,Assiut university
City
Assiut
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ahmed Makhlouf, Professor
Phone
0882414616
Email
amakhloufsalama@yahoo.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
24218013
Citation
Motaze NV, Mbuagbaw L, Young T. Prostaglandins before caesarean section for preventing neonatal respiratory distress. Cochrane Database Syst Rev. 2013 Nov 11;(11):CD010087. doi: 10.1002/14651858.CD010087.pub2.
Results Reference
background
PubMed Identifier
14977896
Citation
Singh M, Patole S, Rane A, Naidoo D, Buettner P. Maternal intravaginal prostaglandin E2 gel before elective caesarean section at term to induce catecholamine surge in cord blood: randomised, placebo controlled study. Arch Dis Child Fetal Neonatal Ed. 2004 Mar;89(2):F131-5. doi: 10.1136/adc.2002.025957.
Results Reference
background
PubMed Identifier
18077440
Citation
Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ. 2008 Jan 12;336(7635):85-7. doi: 10.1136/bmj.39405.539282.BE. Epub 2007 Dec 11.
Results Reference
background
PubMed Identifier
9066188
Citation
Yang JY, Fang LJ, Tsou Yau KI. Labor pain before elective cesarean section reduces neonatal respiratory distress. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1997 Jan-Feb;38(1):38-43.
Results Reference
background

Learn more about this trial

Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome

We'll reach out to this number within 24 hrs